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Abstract We have shown recently that oxidative stress by
chronic hyperglycemia damages the pancreatic L-cells of GK
rats, a model of non-obese type 2 diabetes, which may worsen
diabetic condition and suggested the administration of antiox-
idants as a supportive therapy. To determine if natural
antioxidant K-tocopherol (vitamin E) has beneficial effects on
the glycemic control of type 2 diabetes, GK rats were fed a diet
containing 0, 20 or 500 mg/kg diet K-tocopherol. Intraperitoneal
glucose tolerance test revealed a significant increment of insulin
secretion at 30 min and a significant decrement of blood glucose
levels at 30 and 120 min after glucose loading in the GK rats fed
with high K-tocopherol diet. The levels of glycated hemoglobin
A1c, an indicator of glycemic control, were also reduced.
Vitamin E supplementation clearly ameliorated diabetic control
of GK rats, suggesting the importance of not only dietary
supplementation of natural antioxidants but also other antiox-
idative intervention as a supportive therapy of type 2 diabetic
patients.
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1. Introduction
Overloads of reactive oxygen species (ROS) that exceed the
capacity of the antioxidant system induce oxidative stress in
cells. Oxidative stress is associated with a number of patho-
logical conditions such as in£ammation, atherosclerosis, car-
cinogenesis, aging and reperfusion injury [1]. Oxidative stress
may also play a role in the pathophysiology of diabetes mel-
litus, because prolonged exposure to hyperglycemia causes
non-enzymatic glycation of proteins through Maillard’s reac-
tion and the resulting products such as Schi¡ base and Ama-
dori products can lead to the production of ROS [2^4]. We
and other investigators have shown that the level of 8-hy-
droxy-2P-deoxyguanosine [5], a marker for oxidative stress,
is increased either in the urine or blood mononuclear cells
of type 2 diabetic patients [6,7]. Furthermore, Rehman et al.
reported that multiple DNA base oxidation products are ele-
vated in white blood cell DNA from patients with type 2
diabetes [8].
The GK rat is an inbred rat strain developed by selective
breeding of an outbred colony of Wistar strain rats with high
glucose levels on oral glucose tolerance test. This is one of the
most reliable models for type 2 diabetes because of the many
primary features manifested, including fasting hyperglycemia,
impaired insulin response to glucose, hepatic and peripheral
insulin resistance, and the typical complications [9^14]. We
have reported recently that the pancreatic L-cells of GK
rats, a model of non-obese type 2 diabetes, are oxidatively
stressed, and that chronic hyperglycemia is responsible for
the oxidative stress, causing cytotoxicity in the pancreatic L-
cells [15]. In addition, transfection of antioxidant enzymes in
insulin producing cell lines is reportedly e¡ective against the
toxic action of ROS [16,17]. These observations suggest that
administration of antioxidants to type 2 diabetics may have
bene¢cial e¡ects on glycemic control.
K-Tocopherol (vitamin E) is a major peroxyl radical scav-
enger in cell membranes [18,19]. It inhibits or interrupts chain
reactions of lipid peroxidation, which is the basis for its func-
tion as an antioxidant. Various studies have evaluated the
antioxidant e¡ects of K-tocopherol in prevention of coronary
heart disease and diabetic complications [20^25]. In the
present study, we have examined the e¡ect of dietary K-toco-
pherol supplementation on the diabetic control of GK rats.
2. Materials and methods
2.1. Animals
A total of 24 male GK rats were used in the experiments. Five-
week-old GK rats were divided into three groups and fed the follow-
ing semisynthetic basic diet AIN-76 (Funahashi, Chiba, Japan) [26,27]
with or without K-tocopherol supplementation for 4 weeks: (1) K-
tocopherol-de¢cient diet (n = 8);( 2) K-tocopherol-su⁄cient diet con-
taining 20 mg/kg diet of DL-K-tocopheryl acetate (n = 8) as a control
diet; (3) K-tocopherol-supplemented diet containing 500 mg/kg diet of
DL-K-tocopheryl acetate (n = 8). The animals were given tap water ad
libitum, and maintained at a 12 h light and dark cycle in an air-
conditioned room (22^24‡C) during the experiments.
2.2. Intraperitoneal glucose tolerance test (IPGTT)
After K-tocopherol dietary supplementation, 20% D-glucose solu-
tion (2 g/kg body weight) was injected intraperitoneally to the animals
(n = 5 for each experimental group) in the fasting state. Blood samples
were obtained from the tail vein at 0, 15, 30, 60 and 120 min after the
injection. The blood glucose concentration was determined by an
enzyme-electrode method and the plasma insulin concentration by
an EIA method with insulin assay kit (Morinaga, Kanagawa, Japan).
2.3. Measurement of glycated hemoglobin (HbA1c)
On the day after IPGTT, blood samples were obtained from heart
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under pentobarbital anesthesia (40 mg/kg body weight). HbA1c was
determined by an a⁄nity chromatography method with Glyc-Af-
¢n.GHb kit (Seikagaku-kogyo Co. Ltd., Tokyo, Japan) [28].
2.4. Measurement of pancreatic content of K-tocopherol
The pancreases of the animals (n = 3 for each experimental group)
were removed under pentobarbital anesthesia and frozen. The content
of K-tocopherol in the pancreas was determined by the high perform-
ance liquid chromatography method [29]. The protein determinations
were performed by the Lowry method.
2.5. Statistical analysis
Data are presented as means þ S.E.M. Statistical analyses were per-
formed by an unpaired t test.
3. Results
3.1. Glucose tolerance
To determine the e¡ect of K-tocopherol on the function of
the pancreatic L-cells in GK rats, we carried out IPGTT by
administration of 2 g D-glucose per kg body weight (n = 5 for
each experimental group). While the fasting blood glucose
levels in K-tocopherol-supplemented GK rats were not signi¢-
cantly di¡erent from those in K-tocopherol-de¢cient and -suf-
¢cient GK rats, the peak levels of blood glucose in K-toco-
pherol-supplemented GK rats were signi¢cantly lower than in
K-tocopherol-de¢cient and -su⁄cient GK rats (24.2 þ 0.43
mM vs. 26.2 þ 0.57 mM and 26.8 þ 0.61 mM at 30 min, re-
spectively, P6 0.05) (Fig. 1). The blood glucose levels at 60
min in K-tocopherol-supplemented GK rats were signi¢cantly
lower than in K-tocopherol-de¢cient GK rats (23.9 þ 0.66 mM
vs. 26.4 þ 0.57 mM, P6 0.05). The blood glucose levels at 120
min in K-tocopherol-supplemented GK rats were signi¢cantly
lower than in K-tocopherol-de¢cient and -su⁄cient GK rats
(16.7 þ 0.54 mM vs. 19.2 þ 0.79 mM and 18.6 þ 0.47 mM, re-
spectively, P6 0.05). In addition, the peak levels of plasma
insulin in K-tocopherol-supplemented GK rats were signi¢-
cantly higher than in K-tocopherol-de¢cient and -su⁄cient
GK rats (2125 þ 69.5 pg/ml vs. 1696.2 þ 127.9 pg/ml and
1696.4 þ 138 pg/ml, respectively, P6 0.05).
3.2. Evaluation of diabetic control
No signi¢cant di¡erences in body weight were observed
among K-tocopherol-de¢cient, -su⁄cient and -supplemented
GK rats (Table 1). To evaluate the e¡ect of K-tocopherol
on diabetic control, we measured HbA1c of GK rats after
supplementary diet (n = 7 for each experimental group). The
levels of HbA1c in K-tocopherol-supplemented GK rats were
signi¢cantly lower than in K-tocopherol-de¢cient and -su⁄-
cient GK rats (P6 0.0005 and P6 0.05, respectively). The
levels of HbA1c in K-tocopherol-su⁄cient GK rats were sig-
ni¢cantly lower than in K-tocopherol-de¢cient GK rats
(P6 0.05).
3.3. Pancreatic contents of K-tocopherol
We measured the K-tocopherol contents of pancreas (Table
1); it was not possible to determine the K-tocopherol content
of the pancreatic islets directly because of the limited volume
of samples. The pancreatic K-tocopherol contents in K-toco-
pherol-supplemented GK rats were signi¢cantly higher than in
K-tocopherol-su⁄cient and -de¢cient GK rats (P6 0.001 and
P6 0.0005, respectively).
4. Discussion
Because expression of antioxidant enzymes in the pancreatic
islets is reportedly very low [30,31], the pancreatic L-cells are
thought to be especially vulnerable to the attacks of ROS. We
have previously reported that nitric oxide suppresses glucose
metabolism and results in inhibition of insulin secretion from
the pancreatic L-cells [32]. We have more recently reported
that the chronic hyperglycemic state of type 2 diabetes induces
the oxidative stress on the pancreatic L-cells, causing cytotox-
icity that might worsen clinical diabetic states. These ¢ndings
suggest that antioxidant supplementation to type 2 diabetes
may be e¡ective to improve diabetic states.
In the present study, GK rats were fed a diet with or with-
out antioxidant K-tocopherol supplementation. K-Tocopherol
was indeed accumulated in the pancreas of K-tocopherol-sup-
plemented GK rats. IPGTT revealed that glucose tolerance in
K-tocopherol-supplemented GK rats was ameliorated com-
pared to that in K-tocopherol-de¢cient or -su⁄cient GK
rats. Blood glucose levels were decreased signi¢cantly at 30
min and 120 min in K-tocopherol-supplemented GK rats.
Plasma insulin levels in K-tocopherol-supplemented GK rats
Fig. 1. Glucose tolerance test. Blood glucose (left) and plasma insu-
lin (right) levels after intraperitoneal glucose loading in K-tocopher-
ol-de¢cient (open square), -su⁄cient (open lozenge) and -supple-
mented (closed circle) GK rats. *, P6 0.05 versus K-tocopherol-
de¢cient and -su⁄cient GK rats. 3, P6 0.05 versus K-tocopherol-de-
¢cient GK rats (mean þ S.E.M.).
Table 1







Body weight (g) 201.9 þ 7.6 (n = 8) 211.3 þ 3.9 (n = 8) 217.5 þ 3.4 (n = 8)
HbA1c (%) 10.5 þ 0.88 (n = 7) 9.3 þ 0.3a (n = 7) 8.5 þ 0.15b;c (n = 7)
Pancreatic content of K-tocopherol (Wg/g protein) 5.2 þ 0.38 (n = 3) 39.9 þ 3.1b (n = 3) 254 þ 24b;d (n = 3)
aP6 0.05.
bP6 0.0005 vs. K-tocopherol-de¢cient GK rats.
cP6 0.05.
dP6 0.001 vs. K-tocopherol-su⁄cient GK rats.
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at 30 min were signi¢cantly higher than the others. As a result
of amelioration of defects in glucose metabolism, the levels of
HbA1c were decreased in K-tocopherol-supplemented GK
rats.
There has been a controversy on whether supplementation
of K-tocopherol is e¡ective on decreasing protein glycation in
type 2 diabetes [33]. Fuller et al. reported that K-tocopherol
could not decrease protein glycation but reduced oxidation of
low density lipoprotein [34]. Our study revealed that reduction
of oxidative stress by K-tocopherol decreased blood glucose
levels through improvement of insulin secretion, resulting in
decrement of glycation of hemoglobin in type 2 diabetes.
In conclusion, these ¢ndings suggest that accumulated K-
tocopherol in the pancreatic islets had scavenging e¡ects of
ROS, and resulted in improvements of glucose tolerance and
of diabetic control. It is not known so far how hyperglycemia
causes oxidative stress in the pancreatic L-cells. This signaling
pathway should be elucidated. Our observations indicate that
antioxidant K-tocopherol supplementation to type 2 diabetes
has bene¢cial e¡ects on diabetic control as a supportive ther-
apy. Tanaka et al. [35] reported recently that N-acetyl-L-cys-
teine (NAC) or aminoguanidine prevent glucose-induced oxi-
dative stress in HIT-T15 cells and Zucker diabetic fatty rats.
The combined treatment of K-tocopherol with other natural
antioxidants or antioxidant agents, such as vitamin C, caro-
tenoids, polyphenols, probucol, NAC, aminoguanidine, etc.,
may lead to easier and more stable control of type 2 diabetic
patients.
Acknowledgements: This study was supported in part by Grants-in-
Aids for Scienti¢c Research from the Ministry of Education, Science,
Sports and Culture, Japan, a grant for ‘Research for the Future’
Program from the Japan Society for the Promotion of Science
(JSPS-RFTF97I00201), Grants-in-Aids for Creative Basic Research
(10NP0201) from the Ministry of Education, Science, Sports and
Culture, Japan, and a grant from the Program for Promotion of Basic
Research Activities for Innovative Bioscience (PROBRAIN).
References
[1] Halliwell, B. and Gutteridge, J.M.C. (1999) Free Radicals in
Biology and Medicine, 3rd edn., Clarendon Press, Oxford.
[2] Brownlee, M., Vlassara, H. and Cerami, A. (1984) Ann. Intern.
Med. 101, 527^537.
[3] Sakurai, T. and Tsuchiya, S. (1988) FEBS Lett. 236, 406^410.
[4] Njoroge, F.G. and Monnier, V.M. (1989) Prog. Clin. Biol. Res.
304, 85^107.
[5] Toyokuni, S. (1999) Pathol. Int. 49, 91^102.
[6] Dandona, P., Thusu, K., Cook, S., Snyder, B., Makowski, J.,
Armstrong, D. and Nicotera, T. (1996) Lancet 347, 444^445.
[7] Leinonen, J., Lehtimaki, T., Toyokuni, S., Okada, K., Tanaka,
T., Hiai, H., Ochi, H., Laippala, P., Rantalaiho, V., Wirta, O.,
Pasternack, A. and Alho, H. (1997) FEBS Lett. 417, 150^152.
[8] Rehman, A., Nourooz-Zadeh, J., Moller, W., Tritschler, H., Per-
eira, P. and Halliwell, B. (1999) FEBS Lett. 448, 120^122.
[9] Goto, Y., Suzuki, K., Sasaki, M.M. and Abe, S. (1998) in: Fron-
tiers in Diabetes Research. Lessons from Animal Diabetes II
(Shafrir, E. and Renold, A.E., Eds.), pp. 301^303, John Libbey,
London.
[10] Goto, Y., Suzuki, K., Ono, T., Sasaki, M. and Toyota, T. (1988)
Adv. Exp. Med. Biol. 246, 29^31.
[11] Portha, B., Serradas, P., Bailbe, D., Suzuki, K., Goto, Y. and
Giroix, M.H. (1991) Diabetes 40, 486^491.
[12] Bisbis, S., Bailbe, D., Tormo, M.A., Picarel, B.F., Derouet, M.,
Simon, J. and Portha, B. (1993) Am. J. Physiol. 265, E807^
E813.
[13] Tsuura, Y., Ishida, H., Okamoto, Y., Kato, S., Sakamoto, K.,
Horie, M., Ikeda, H., Okada, Y. and Seino, Y. (1993) Diabetes
42, 1446^1453.
[14] Kato, S., Ishida, H., Tsuura, Y., Tsuji, K., Nishimura, M., Ho-
rie, M., Taminato, T., Ikehara, S., Odaka, H., Ikeda, I., Okada,
Y. and Seino, Y. (1996) J. Clin. Invest. 97, 2417^2425.
[15] Ihara, Y., Toyokuni, S., Uchida, K., Odaka, H., Tanaka, T.,
Ikeda, H., Hiai, H., Seino, Y. and Yamada, Y. (1999) Diabetes
48, 927^932.
[16] Kubisch, H.M., Wang, J., Bray, T.M. and Phillips, J.P. (1997)
Diabetes 46, 1563^1566.
[17] Hohmeier, H.E., Thigpen, A., Tran, V.V., Davis, R. and New-
gard, C.B. (1998) J. Clin. Invest. 101, 1811^1820.
[18] Witting, L.A. (1980) in: Free Radicals in Biology (Pryor, W.A.,
Ed.), Vol. 4, pp. 295^319, Academic Press, New York.
[19] Brigelius-Flohe, R. and Traber, M.G. (1999) FASEB J. 13, 1145^
1155.
[20] Nickander, K.K., Schmelzer, J.D., Rohwer, D.A. and Low, P.A.
(1994) J. Neurol. Sci. 126, 6^14.
[21] Rimm, E.B. and Stampfer, M.J. (1997) Curr. Opin. Cardiol. 12,
188^194.
[22] Rosen, P. (1998) Mol. Cell. Biochem. 188, 103^111.
[23] Spencer, A.P., Carson, D.S. and Crouch, M.A. (1999) Arch.
Intern. Med. 159, 1313^1320.
[24] Bursell, S.E., Clermont, A.C., Aiello, L.P., Aiello, L.M., Schloss-
man, D.K., Feener, E.P., La¡el, L. and King, G.L. (1999) Dia-
betes Care 22, 1245^1251.
[25] Oranje, W.A. and Wol¡enbuttel, B.H. (1999) J. Lab. Clin. Med.
134, 19^32.
[26] Reeves, P.G. (1989) J. Nutr. 119, 1081^1082.
[27] Meydani, M., Lipman, R.D., Han, S.N., Wu, D., Beharka, A.,
Martin, K.R., Bronson, R., Cao, G., Smith, D. and Meydani,
S.N. (1998) Ann. N.Y. Acad. Sci. 854, 352^360.
[28] Talwar, D., Barr, B.B., Kesson, C.M. and Robb, D.A. (1983)
Clin. Chim. Acta 29, 61^67.
[29] Browne, W.R. and Armstrong, D. (1998) in: Free Radical and
Antioxidant Protocols, Methods in Molecular Biology (Arm-
strong, D., Ed.), Vol. 108, pp. 269^275, Humana Press Inc.,
Totowa, NJ.
[30] Lenzen, S., Drinkgern, J. and Tiedge, M. (1996) Free Radic. Biol.
Med. 20, 463^466.
[31] Tiedge, M., Lortz, S., Drinkgern, J. and Lenzen, S. (1997) Dia-
betes 46, 1733^1742.
[32] Tsuura, y., Ishida, H., Shinomura, T., Nishimura, M. and Seino,
Y. (1998) Biochem. Biophys. Res. Commun. 252, 34^39.
[33] Paolisso, G., D’Amore, A., Guigliano, D., Ceriello, A., Varric-
chio, M. and D’Onofrio, F. (1993) Am. J. Clin. Nutr. 57, 650^
656.
[34] Fuller, C.J., Chandalia, M., Garg, A., Grundy, S.M. and Jialal, I.
(1996) Am. J. Clin. Nutr. 63, 753^759.
[35] Tanaka, Y., Gleason, C.E., Tran, P.O.T., Harmon, J.S. and Rob-
ertson, R.P. (1999) Proc. Natl. Acad. Sci. USA 96, 10857^
10862.
FEBS 23623 27-4-00
Y. Ihara et al./FEBS Letters 473 (2000) 24^2626
